Global /Hong Kong /Healthcare /Biotechnology /2257

Sirnaomics Ltd.

2257

• SHEK: 2257 • Delayed

6.40HKD -2.9%

0.8168 USD

As of 5 June 2026, Sirnaomics Ltd. has a market cap of $91.59M USD, ranking #26180 globally and #549 in Hong Kong. It ranks #2350 in the Healthcare sector, and #452 in the Biotechnology industry.

Global Rank

26180

Country Rank

549

Sector Rank

2350

Industry Rank

452

Key Stats

Market Cap

$91.59MUSD

717.64M HKD

Enterprise Value

$72.93MUSD

571.45M HKD

EBITDA (TTM)

-$13.02MUSD

-101.98M HKD

Net Income (TTM)

-$14.31MUSD

-112.1M HKD

PB Ratio

-3.8

Company Profile

Country (HQ)

Hong Kong

Sector

Healthcare

Industry

Biotechnology

CEO

Hung Fai Poon open_in_new

Employees

Founded

2007

Website

sirnaomics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.9%	-10%	7.9%	-23%	-37%	-17%	111%	-88%	-92%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	2257 圣诺医药 ISIN: KYG2050P1028 Shares Out.: Shares Outstanding: 109.722M¹ Shares Float: 72.424M² TV: TradingView: HKEX: 2257 SA: Stock Analysis: HKG: 2257 YF: Yahoo Finance: 2257.HK GF: Google Finance: HKG: 2257 BA: Barron's: 2257 MS: Morningstar: XHKG: 02257	6.40 HKD	TV: TradingView: HKEX: 2257 SA: Stock Analysis: HKG: 2257 YF: Yahoo Finance: 2257.HK GF: Google Finance: HKG: 2257 BA: Barron's: 2257 MS: Morningstar: XHKG: 02257

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Sirnaomics Ltd.

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases. In addition, it is developing STP247G to treat complement-mediated immunologic diseases; STP237G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension. The company was founded in 2007 and is based in Wan Chai, Hong Kong.

Similar Companies

Industry: Biotechnology (Hong Kong)

Name	Market Cap (USD) diff.	PE	Country
SinoMab BioScience Ltd. SHEK: 3681	$270.77M 2.12B HKD 196%	-	Hong Kong
Chia Tai Enterprises International Ltd. SHEK: 3839	$265.45M 2.08B HKD 190%	8.3	Hong Kong
China NT Pharma Group Company Ltd. SHEK: 1011	$81.15M 635.83M HKD -11%	-	Hong Kong

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 199K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 174K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 52K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 48K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 47K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 47K%	37.2	Switzerland

chevron_leftBack